+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil



Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil



Journal of Clinical Oncology 11(12): 2411-2416



Purpose: To establish the optimum biologic dose and maximal-tolerated dose (MTD) of once-daily, subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast (RhuGM-CSF) in patients with breast cancer. Patients and Methods: Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m-2, doxorubicin 50 mg/m-2, and fluorouracil 500 mg/m-2 (CAF) intravenously (IV) once every 3 weeks. RhuGM-CSF was administered subcutaneously once daily for 14 days after the second and third CAF cycles, at one of three dose levels. Results: The 125-mu-g/m-2/d RhuGM-CSF dose level shortened the duration of neutropenia in only one of three patients. The 250-mu-g/m-2/d level was effective in shortening the duration of the neutropenic nadir ( lt .5 times 10-9/dL) by 2 or more days in five of six patients. The 500-mu-g/m-2/d level caused severe toxicity (chest pain, two patients; deep vein thrombosis, one patient) in three of eight patients. Conclusion: RhuGM-CSF administered once daily at the 250-mu-g/m-2/d level is well tolerated and effective in shortening the duration of the neutrophil nadir by 2 or more days after CAF therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009183260

Download citation: RISBibTeXText

PMID: 8246030

DOI: 10.1200/jco.1993.11.12.2411


Related references

A phase i trial with recombinant human granulocyte macrophage colony stimulating factor derived from yeast rhugm csf in patients with breast cancer receiving caf chemotherapy in adjuvant and metastatic disease. Breast Cancer Research & Treatment 19(2): 168, 1991

The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project. American Journal of Clinical Oncology 17(5): 374-81; Discussion 382, 1994

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Annals of Oncology 5(8): 709-716, 1994

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology 17(8): 1205-1212, 2006

Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein versus GM-CSF in patients with advanced breast cancer. Blood 87(6): 2205-2211, 1996

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood 86(8): 2913-2921, 1995

The Efficacy of Recombinant Human Granulocyte Colony-Stimulating Factor and Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor in Permitting the Administration of Higher Doses of Cyclophosphamide in a Doxorubicin-Cyclophosphamide Combination. American Journal of Clinical Oncology 17(5): 374-381, 1994

A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. British Journal of Cancer 69(3): 537-540, 1994

Comparison of neutrophil and monocyte function by microbicidal cell-kill assay in patients with cancer receiving granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, or no cytokine after cytotoxic chemotherapy: a phase II trial. American Journal of Clinical Oncology 21(3): 308-312, 1998

A phase i dose intensity trial for node positive breast cancer patients using adjuvant cyclophosphamide c doxorubicin a and granulocyte colony stimulating factor gcsf. Proceedings of the American Association for Cancer Research Annual Meeting 33: 256, 1992

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clinical Breast Cancer 3(4): 268-275, 2002

Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer. Journal of Cancer Research and Clinical Oncology 125(8-9): 500-504, 1999

A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. Acta Oncologica (stockholm). 33(8): 925-929, 1994

Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma. Medical Oncology 22(3): 257-267, 2005

A phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia receiving high-dose cytarabine during induction ECOG 3997. Blood 96(11 Part 1): 323a, 2000